Annual CFO
-$44.59 M
-$12.27 M-37.96%
31 December 2023
Summary:
Aptose Biosciences annual cash flow from operations is currently -$44.59 million, with the most recent change of -$12.27 million (-37.96%) on 31 December 2023. During the last 3 years, it has fallen by -$10.70 million (-31.57%). APTO annual CFO is now -1726.34% below its all-time high of -$2.44 million, reached on 31 May 1999.APTO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$10.38 M
-$4.60 M-79.58%
30 September 2024
Summary:
Aptose Biosciences quarterly cash flow from operations is currently -$10.38 million, with the most recent change of -$4.60 million (-79.58%) on 30 September 2024. Over the past year, it has increased by +$160.00 thousand (+1.52%). APTO quarterly CFO is now -5038.60% below its all-time high of $210.10 thousand, reached on 31 May 1999.APTO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$37.18 M
+$160.00 K+0.43%
30 September 2024
Summary:
Aptose Biosciences TTM cash flow from operations is currently -$37.18 million, with the most recent change of +$160.00 thousand (+0.43%) on 30 September 2024. Over the past year, it has increased by +$6.81 million (+15.47%). APTO TTM CFO is now -3872.22% below its all-time high of -$935.90 thousand, reached on 31 August 1997.APTO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.0% | +1.5% | +15.5% |
| 3 y3 years | -31.6% | -28.8% | +1.2% |
| 5 y5 years | -92.1% | -100.2% | -78.5% |
APTO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -38.0% | at low | -79.6% | +35.3% | -15.0% | +17.5% |
| 5 y | 5 years | -106.8% | at low | -100.2% | +35.3% | -78.5% | +17.5% |
| alltime | all time | -1726.3% | at low | -5038.6% | +35.3% | -3872.2% | +17.5% |
Aptose Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.38 M(+79.6%) | -$37.18 M(-0.4%) |
| June 2024 | - | -$5.78 M(-50.9%) | -$37.34 M(-17.1%) |
| Mar 2024 | - | -$11.76 M(+27.0%) | -$45.05 M(+1.0%) |
| Dec 2023 | -$44.59 M(+38.0%) | -$9.26 M(-12.1%) | -$44.59 M(+1.4%) |
| Sept 2023 | - | -$10.54 M(-21.9%) | -$43.98 M(+8.8%) |
| June 2023 | - | -$13.49 M(+19.4%) | -$40.42 M(+19.0%) |
| Mar 2023 | - | -$11.30 M(+30.6%) | -$33.98 M(+5.1%) |
| Dec 2022 | -$32.32 M(-25.4%) | -$8.65 M(+24.0%) | -$32.32 M(-18.6%) |
| Sept 2022 | - | -$6.98 M(-1.0%) | -$39.72 M(-2.6%) |
| June 2022 | - | -$7.05 M(-26.9%) | -$40.80 M(-4.2%) |
| Mar 2022 | - | -$9.64 M(-39.9%) | -$42.57 M(-1.7%) |
| Dec 2021 | -$43.30 M(+27.8%) | -$16.04 M(+99.1%) | -$43.30 M(+15.1%) |
| Sept 2021 | - | -$8.06 M(-8.7%) | -$37.61 M(-0.6%) |
| June 2021 | - | -$8.82 M(-14.9%) | -$37.84 M(+4.7%) |
| Mar 2021 | - | -$10.38 M(+0.2%) | -$36.16 M(+6.7%) |
| Dec 2020 | -$33.89 M(+57.2%) | -$10.35 M(+24.9%) | -$33.89 M(+13.8%) |
| Sept 2020 | - | -$8.29 M(+16.0%) | -$29.77 M(+11.6%) |
| June 2020 | - | -$7.14 M(-11.9%) | -$26.67 M(+7.6%) |
| Mar 2020 | - | -$8.11 M(+30.2%) | -$24.80 M(+15.0%) |
| Dec 2019 | -$21.56 M(-7.1%) | -$6.23 M(+20.2%) | -$21.56 M(+3.5%) |
| Sept 2019 | - | -$5.18 M(-1.6%) | -$20.83 M(+3.6%) |
| June 2019 | - | -$5.27 M(+8.1%) | -$20.11 M(-16.3%) |
| Mar 2019 | - | -$4.87 M(-11.4%) | -$24.03 M(+3.5%) |
| Dec 2018 | -$23.21 M(+127.0%) | -$5.50 M(+23.1%) | -$23.21 M(+13.0%) |
| Sept 2018 | - | -$4.47 M(-51.3%) | -$20.54 M(+13.1%) |
| June 2018 | - | -$9.18 M(+126.5%) | -$18.17 M(+56.3%) |
| Mar 2018 | - | -$4.05 M(+42.8%) | -$11.62 M(+13.7%) |
| Dec 2017 | -$10.22 M(-17.5%) | -$2.84 M(+35.8%) | -$10.22 M(-0.8%) |
| Sept 2017 | - | -$2.09 M(-20.8%) | -$10.31 M(-2.7%) |
| June 2017 | - | -$2.64 M(-0.5%) | -$10.59 M(-8.3%) |
| Mar 2017 | - | -$2.65 M(-9.2%) | -$11.56 M(-6.7%) |
| Dec 2016 | -$12.39 M(+25.3%) | -$2.92 M(+22.8%) | -$12.39 M(-1.8%) |
| Sept 2016 | - | -$2.38 M(-34.0%) | -$12.62 M(+7.3%) |
| June 2016 | - | -$3.60 M(+3.4%) | -$11.76 M(+1.2%) |
| Mar 2016 | - | -$3.48 M(+10.5%) | -$11.62 M(+17.5%) |
| Dec 2015 | -$9.89 M(+70.9%) | -$3.15 M(+107.6%) | -$9.89 M(+46.8%) |
| Sept 2015 | - | -$1.52 M(-56.2%) | -$6.74 M(+29.1%) |
| June 2015 | - | -$3.47 M(+97.6%) | -$5.22 M(-4.8%) |
| Mar 2015 | - | -$1.75 M(-52.9%) | -$5.48 M(-30.3%) |
| Dec 2014 | -$5.79 M(-26.4%) | - | - |
| May 2014 | -$7.87 M(+59.3%) | -$3.73 M(+100.0%) | -$7.87 M(+57.7%) |
| Feb 2014 | - | -$1.86 M(+33.8%) | -$4.99 M(+16.5%) |
| Nov 2013 | - | -$1.39 M(+57.3%) | -$4.28 M(+1.1%) |
| Aug 2013 | - | -$885.00 K(+4.3%) | -$4.24 M(-14.2%) |
| May 2013 | -$4.94 M(+53.7%) | -$848.60 K(-26.6%) | -$4.94 M(+13.3%) |
| Feb 2013 | - | -$1.16 M(-14.1%) | -$4.36 M(+1.0%) |
| Nov 2012 | - | -$1.35 M(-15.2%) | -$4.31 M(+16.7%) |
| Aug 2012 | - | -$1.59 M(+491.9%) | -$3.70 M(+15.1%) |
| May 2012 | -$3.21 M(-46.1%) | -$268.10 K(-75.9%) | -$3.21 M(-17.7%) |
| Feb 2012 | - | -$1.11 M(+52.7%) | -$3.90 M(-15.8%) |
| Nov 2011 | - | -$729.10 K(-33.9%) | -$4.64 M(-28.0%) |
| Aug 2011 | - | -$1.10 M(+15.1%) | -$6.44 M(+8.0%) |
| May 2011 | -$5.96 M | -$957.90 K(-48.2%) | -$5.96 M(+13.6%) |
| Feb 2011 | - | -$1.85 M(-27.0%) | -$5.25 M(+2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2010 | - | -$2.53 M(+306.2%) | -$5.13 M(+58.0%) |
| Aug 2010 | - | -$623.30 K(+155.1%) | -$3.25 M(-7.9%) |
| May 2010 | -$3.53 M(-46.7%) | -$244.30 K(-85.9%) | -$3.53 M(-35.2%) |
| Feb 2010 | - | -$1.73 M(+167.7%) | -$5.44 M(+10.4%) |
| Nov 2009 | - | -$647.50 K(-28.2%) | -$4.93 M(-13.3%) |
| Aug 2009 | - | -$901.20 K(-58.3%) | -$5.68 M(-14.1%) |
| May 2009 | -$6.62 M(-35.4%) | -$2.16 M(+77.1%) | -$6.62 M(-6.6%) |
| Feb 2009 | - | -$1.22 M(-13.2%) | -$7.09 M(-17.7%) |
| Nov 2008 | - | -$1.40 M(-23.5%) | -$8.61 M(-12.7%) |
| Aug 2008 | - | -$1.84 M(-30.2%) | -$9.86 M(-3.8%) |
| May 2008 | -$10.25 M(+74.2%) | -$2.63 M(-4.1%) | -$10.25 M(+24.9%) |
| Feb 2008 | - | -$2.74 M(+3.0%) | -$8.21 M(+18.7%) |
| Nov 2007 | - | -$2.66 M(+19.6%) | -$6.91 M(+6.9%) |
| Aug 2007 | - | -$2.22 M(+280.6%) | -$6.47 M(+9.9%) |
| May 2007 | -$5.88 M(-50.4%) | -$584.20 K(-59.6%) | -$5.88 M(-20.4%) |
| Feb 2007 | - | -$1.45 M(-34.6%) | -$7.39 M(-22.9%) |
| Nov 2006 | - | -$2.21 M(+34.9%) | -$9.58 M(+1.3%) |
| Aug 2006 | - | -$1.64 M(-21.5%) | -$9.46 M(-20.3%) |
| May 2006 | -$11.87 M(-20.5%) | -$2.09 M(-42.6%) | -$11.87 M(-5.8%) |
| Feb 2006 | - | -$3.64 M(+74.2%) | -$12.59 M(+5.5%) |
| Nov 2005 | - | -$2.09 M(-48.4%) | -$11.94 M(-17.7%) |
| Aug 2005 | - | -$4.05 M(+43.7%) | -$14.50 M(-2.8%) |
| May 2005 | -$14.92 M(-27.6%) | -$2.82 M(-5.6%) | -$14.92 M(-20.6%) |
| Feb 2005 | - | -$2.98 M(-35.9%) | -$18.78 M(-7.2%) |
| Nov 2004 | - | -$4.65 M(+4.2%) | -$20.23 M(-2.8%) |
| Aug 2004 | - | -$4.46 M(-33.2%) | -$20.81 M(+1.0%) |
| May 2004 | -$20.60 M(+137.4%) | -$6.68 M(+50.5%) | -$20.60 M(+24.3%) |
| Feb 2004 | - | -$4.44 M(-15.1%) | -$16.57 M(+11.7%) |
| Nov 2003 | - | -$5.23 M(+22.8%) | -$14.84 M(+30.9%) |
| Aug 2003 | - | -$4.25 M(+60.2%) | -$11.33 M(+30.6%) |
| May 2003 | -$8.68 M(+11.3%) | -$2.66 M(-1.9%) | -$8.68 M(+5.1%) |
| Feb 2003 | - | -$2.71 M(+57.4%) | -$8.25 M(-3.8%) |
| Nov 2002 | - | -$1.72 M(+7.7%) | -$8.58 M(+15.5%) |
| Aug 2002 | - | -$1.60 M(-28.6%) | -$7.42 M(-4.7%) |
| May 2002 | -$7.79 M(+24.0%) | -$2.23 M(-26.3%) | -$7.79 M(+13.8%) |
| Feb 2002 | - | -$3.03 M(+433.9%) | -$6.85 M(+18.0%) |
| Nov 2001 | - | -$567.20 K(-71.1%) | -$5.80 M(-8.0%) |
| Aug 2001 | - | -$1.96 M(+52.4%) | -$6.30 M(+0.3%) |
| May 2001 | -$6.28 M(+75.6%) | -$1.29 M(-35.0%) | -$6.28 M(+0.8%) |
| Feb 2001 | - | -$1.98 M(+85.6%) | -$6.23 M(-0.3%) |
| Nov 2000 | - | -$1.07 M(-45.0%) | -$6.25 M(+19.0%) |
| Aug 2000 | - | -$1.94 M(+57.3%) | -$5.25 M(+46.8%) |
| May 2000 | -$3.58 M(+46.6%) | -$1.24 M(-38.3%) | -$3.58 M(+67.8%) |
| Feb 2000 | - | -$2.00 M(+2686.6%) | -$2.13 M(+84.9%) |
| Nov 1999 | - | -$71.90 K(-73.1%) | -$1.15 M(-29.4%) |
| Aug 1999 | - | -$267.60 K(-227.4%) | -$1.63 M(-33.1%) |
| May 1999 | -$2.44 M(-19.2%) | $210.10 K(-120.5%) | -$2.44 M(-25.6%) |
| Feb 1999 | - | -$1.02 M(+85.5%) | -$3.28 M(+1.2%) |
| Nov 1998 | - | -$551.90 K(-48.7%) | -$3.24 M(+2.6%) |
| Aug 1998 | - | -$1.08 M(+70.3%) | -$3.16 M(+4.6%) |
| May 1998 | -$3.02 M(+15.6%) | -$631.80 K(-35.8%) | -$3.02 M(+26.4%) |
| Feb 1998 | - | -$983.50 K(+109.4%) | -$2.39 M(+70.0%) |
| Nov 1997 | - | -$469.60 K(-49.8%) | -$1.41 M(+50.2%) |
| Aug 1997 | - | -$935.90 K | -$935.90 K |
| May 1997 | -$2.61 M | - | - |
FAQ
- What is Aptose Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Aptose Biosciences?
- What is Aptose Biosciences annual CFO year-on-year change?
- What is Aptose Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aptose Biosciences?
- What is Aptose Biosciences quarterly CFO year-on-year change?
- What is Aptose Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Aptose Biosciences?
- What is Aptose Biosciences TTM CFO year-on-year change?
What is Aptose Biosciences annual cash flow from operations?
The current annual CFO of APTO is -$44.59 M
What is the all time high annual CFO for Aptose Biosciences?
Aptose Biosciences all-time high annual cash flow from operations is -$2.44 M
What is Aptose Biosciences annual CFO year-on-year change?
Over the past year, APTO annual cash flow from operations has changed by -$12.27 M (-37.96%)
What is Aptose Biosciences quarterly cash flow from operations?
The current quarterly CFO of APTO is -$10.38 M
What is the all time high quarterly CFO for Aptose Biosciences?
Aptose Biosciences all-time high quarterly cash flow from operations is $210.10 K
What is Aptose Biosciences quarterly CFO year-on-year change?
Over the past year, APTO quarterly cash flow from operations has changed by +$160.00 K (+1.52%)
What is Aptose Biosciences TTM cash flow from operations?
The current TTM CFO of APTO is -$37.18 M
What is the all time high TTM CFO for Aptose Biosciences?
Aptose Biosciences all-time high TTM cash flow from operations is -$935.90 K
What is Aptose Biosciences TTM CFO year-on-year change?
Over the past year, APTO TTM cash flow from operations has changed by +$6.81 M (+15.47%)